This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.0 (glycogen storage disease) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | Glycogen storage disease type VII, glycogen storage disease type 7, muscle phosphofructokinase deficiency, Glycogen storage disease type VII (GSD VII), Phosphofructokinase (PFK) deficiency, Muscle PFK deficiency, PFKM-related myopathy |
| C. Adult onset | Intermediate likelihood of first presenting in adulthood — the classic form (exercise intolerance + hemolytic anemia) is found in childhood, but the late-onset form (fixed proximal muscle weakness) may first be diagnosed in middle age (30s–50s). Some cases are first diagnosed when the patient presents with myoglobinuria after overwork or strenuous exercise in adulthood. |
| 1. History | 1965 first description of muscle PFK deficiency by Tarui Seiichiro et al. of Japan. The association with red cell PFK deficiency was subsequently elucidated. |
| 2. Causes | Pathogenic variants in the PFKM gene (12q13.11) → deficiency of the muscle-type PFK M subunit → glycolytic defect → muscle energy deficiency + red blood cell hemolysis. |
| 3. Genetics | Autosomal recessive. PFKM gene 12q13.11. Founder variants (p.Arg41Ter, exon 5 deletion) are frequent in Ashkenazi Jews. |
| 4. General epidemiology | Ultra-rare disease. Hundreds of cases reported worldwide. Relatively frequent in Japanese and Ashkenazi Jews. |
| 5. Pathophysiology | PFK deficiency → impaired conversion of fructose-6-phosphate to fructose-1,6-bisphosphate → blockade of glycolysis → muscle ATP shortage (exercise intolerance) + accumulation of glucose-6-phosphate → excessive accumulation of glycogen and glucose (GSD). Partial red cell PFK deficiency → oxidative damage → hemolytic anemia. |
| 6. Symptoms | Exercise-induced myalgia and cramps, exercise intolerance, myoglobinuria, compensated hemolytic anemia and jaundice, nausea and vomiting after exercise. Nonclassic phenotypes: severe infantile form (cardiomyopathy, respiratory failure, early death), late-onset form (fixed muscle weakness), isolated hemolytic anemia form. |
| 7. Signs | Markedly elevated serum CK after exercise, myoglobinuria (reddish-brown urine), increased reticulocytes, mildly elevated bilirubin with predominance of unconjugated (indirect) bilirubin, elevated uric acid. Decreased exercise performance after glucose injection (glucose paradox). Electromyography: nonspecific. |
| 8. Screening | On the non-ischemic forearm exercise test, elevated ammonia with no rise in lactate is characteristic. Measurement of serum CK and reticulocyte count. |
| 9. Diagnosis | PFKM molecular genetic testing (definitive diagnosis). Measurement of PFK enzyme activity on muscle biopsy. Red cell PFK activity (characteristically reduced by 50%). Histology: accumulation of PAS-positive glycogen + polyglucosan. |
| 10. Treatment | No curative treatment. Avoid strenuous exercise, high-protein, low-carbohydrate diet (to promote use of fat and protein for energy), ketogenic diet trial (reported in some cases). Folate supplementation (for hemolytic anemia). Fluid therapy in acute rhabdomyolysis. |
| 11. Prognosis | The classic form has a relatively stable course when exercise is restricted. With repeated acute rhabdomyolysis and myoglobinuria there is a risk of acute kidney failure. The severe infantile form carries a high risk of early death. |
| 12. Prevention | Genetic counseling, prenatal testing. Low-intensity warm-up before exercise, avoid high-intensity exercise, adequate fluid intake. Limit activity during fever. |
| 13. References | Tarui S et al. (1965) first description and 9 other papers. |
The history of Tarui disease (GSD VII) began in 1965 when the team of Professor Seiichiro Tarui of the Faculty of Medicine at Osaka University in Japan found complete deficiency of muscle phosphofructokinase (PFK) in siblings who presented with exercise intolerance and myalgia. This study was published in Biochemical and Biophysical Research Communications, and the disease was named "Tarui disease" or "glycogen storage disease type VII (GSD type VII)."
Tarui biochemically demonstrated that, although exercise intolerance similar to McArdle disease (GSD V, muscle phosphorylase deficiency) was present, it was due to a different enzyme deficiency. The key finding was the so-called "glucose paradox (out-of-wind phenomenon)," in which exercise capacity actually decreases after glucose infusion in patients, which explained the characteristic paradoxical reaction in which, in PFK deficiency, glucose-6-phosphate and fructose-6-phosphate accumulate and glycolysis is blocked even further.
In the 1970s–1980s it was found that PFK activity is also reduced by about 50% in red blood cells, elucidating the mechanism of hemolytic anemia. PFK is a tetrameric enzyme composed of three subunits, M (muscle type), L (liver type) and P (platelet type), forming the M4 isozyme in muscle and the ML hybrid isozyme in red blood cells. PFKM gene variants affect both muscle M4 PFK and red cell M2L2 PFK, explaining the distinctive clinical picture of myopathy accompanied by hemolytic anemia.
In 1992 the causative gene of Tarui disease, PFKM, was found to be located on the long arm of chromosome 12 (12q13.11), and many pathogenic variants were subsequently identified. In particular, the exon 5 deletion variant and the p.Arg41Ter (nonsense) variant have been found at high frequency in Ashkenazi Jewish populations owing to the founder effect. Since the 2000s, with the introduction of next-generation sequencing (NGS), patients with atypical phenotypes who could not previously be diagnosed began to be confirmed molecularly, and various phenotypes such as the severe infantile form, the late-onset form and the isolated hemolytic anemia form were described. In Korea as well, sporadic cases have been reported since the 2010s at university hospital neuromuscular disease clinics, and it is designated by the Korea Disease Control and Prevention Agency (KDCA) as an ultra-rare disease (V117).
Tarui disease (GSD VII) is an autosomal recessive genetic disease caused by pathogenic variants in the PFKM gene (phosphofructokinase, muscle type; 12q13.11), resulting in deficiency or severe reduction of the muscle-type phosphofructokinase M subunit (PFK-M subunit). PFK is the rate-limiting enzyme that catalyzes the conversion of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6BP) in glycolysis. This reaction is virtually irreversible in glycolysis and is precisely regulated by energy-sensing mechanisms (AMP/ATP ratio).
The PFK enzyme has a tetrameric structure composed of three subunit gene products (M: muscle type, L: liver type, P: platelet/brain type). In mature muscle cells PFK is expressed as the M4 isozyme (composed only of four PFKM subunits), and with PFKM variants this isozyme completely loses function. In mature red blood cells, multiple isozymes with mixed PFKM and PFKL (liver type) subunits (M4, M3L1, M2L2, M1L3, L4) are expressed, and with PFKM variants all isozymes containing the M subunit lose function, so red cell PFK activity falls to about 50% of the total. This is the core of the distinctive pathophysiology in which hemolytic anemia accompanies myopathy.
More than 80 pathogenic variants have been reported in the PFKM gene to date. Two variants due to the founder effect are found at high frequency in the Ashkenazi Jewish population: (1) a deletion of the exon 5 splice site (c.237+1G>C) and (2) the p.Arg41Ter (c.120C>A) nonsense variant. In Japanese patients, variants such as p.Asp590Asn and c.822del have been repeatedly reported. Various missense and frameshift variants have also been described in Chinese, European and Middle Eastern populations.
The main consequences of PFK deficiency are three: (1) shortage of ATP supply due to blockade of glycolysis in muscle cells (energy deficiency during exercise), (2) stimulation of glycogen synthesis due to intramuscular accumulation of glucose-6-phosphate and fructose-6-phosphate (excessive glycogen accumulation), and (3) a state vulnerable to oxidative damage due to partial PFK deficiency in red blood cells (hemolytic anemia). The glucose paradox (or out-of-wind phenomenon) is a phenomenon in which, after glucose infusion, the PFK barrier is strengthened by increased fructose-6-phosphate so that exercise capacity actually decreases, and it is a clinical clue specific to GSD VII.
The PFKM gene is located on the long arm of chromosome 12 (12q13.11) and is composed of a total of 24 exons. The transcribed PFK-M subunit protein is composed of 780 amino acids and has a structure in which two functionally identical half-molecules are arranged in tandem. The enzyme functions as a tetramer (about 340 kDa), and each subunit contains an ATP-binding site, a fructose-6-phosphate-binding site and an allosteric regulatory site (activated by AMP, ADP and Pi; inhibited by ATP and citrate).
The mode of inheritance is autosomal recessive. Heterozygous carriers are generally asymptomatic but rarely show mild exercise intolerance or mild hemolytic anemia. The genotype–phenotype correlation is as follows. Generally, patients with premature termination variants (nonsense, frameshift, large deletion) on both alleles show the classic myopathy + hemolytic anemia phenotype. Some missense variants, especially variants in the regulatory site or near the dimer interface, affect enzyme assembly and stability and can cause a severe phenotype. The severe infantile form is presumed to occur when PFK function is severely impaired not only in muscle using the M subunit but also in cardiac muscle.
PFK is composed of three subunits, muscle type (M), liver type (L) and platelet/brain type (P), encoded by the PFKM (12q13.11), PFKL (21q22.3) and PFKP (10p15.2) genes, respectively. PFKL variants alone in red blood cells (hemolytic anemia without GSD) have also been reported (liver-type PFK deficiency). Therefore, in clinical differentiation, panel testing including the PFKM, PFKL and PFKP genes is recommended.
In terms of genetic counseling, when both parents are PFKM heterozygous carriers, 25% of their children may be affected. Prenatal genetic testing (chorionic villus sampling, amniocentesis) and preimplantation genetic testing (PGT-M) are presented as options. Molecular genetic testing of siblings allows early diagnosis and education on lifestyle management. Because specific founder variants are frequent in Japanese and Ashkenazi Jews, in patients with this ethnic background it is efficient to perform targeted testing for those variants first.
Tarui disease (GSD VII) is a very rare form even among glycogen storage diseases, with only a few hundred confirmed cases reported worldwide. The exact prevalence is unknown, but it is an ultra-rare disease, and some estimates suggest a rarity of 1 in 1 million or greater. Because diagnosis is difficult and mild or atypical phenotypes often go undiagnosed, the actual number of patients is expected to exceed the number of reported cases.
The relatively frequent occurrence in specific ethnic groups is due to the founder effect. In the Ashkenazi Jewish population, two major founder variants (exon 5 deletion, p.Arg41Ter) are found at high frequency, and the prevalence of GSD VII in this population is markedly higher than in the general population. Relatively many cases have also been reported in Japanese patients, which appears to be due to active diagnostic activity in Japan together with the fact that the first describer, Professor Tarui, was Japanese. Sporadic cases have also been reported in Italy, Spain, the United States, Israel and elsewhere.
The sex distribution is equal in men and women, following autosomal recessive inheritance. However, some reports tend to report more male patients, which suggests that women may develop symptoms late or have diagnostic delay because of relatively lower levels of exercise activity. The age of onset differs according to phenotype. The classic form first presents in childhood (ages 1–10) with exercise intolerance and myalgia, and the severe infantile form shows severe hypotonia and cardiomyopathy from just after birth, in some cases leading to death within months. In the late-onset form, patients often first visit a medical institution in middle age with fixed proximal muscle weakness.
The occurrence in Korea is extremely rare, and only a few case reports have been made. It is included in the KDCA list of ultra-rare diseases, but the exact number of registered patients in Korea is not known. The Ashkenazi Jewish–specific founder variants are rare in Koreans, and missense or splicing variants of the PFKM gene are reported to be found in Korean patients.
The pathophysiology of Tarui disease is due to blockade of a key step in glycolysis catalyzed by the enzyme phosphofructokinase (PFK). PFK uses ATP and fructose-6-phosphate (F6P) as substrates to produce fructose-1,6-bisphosphate (F1,6BP) and ADP. This reaction is the irreversible committed step in glycolysis and is precisely regulated by cellular energy state (ATP/AMP ratio), citrate concentration and pH. In muscle cells deficient in the PFK-M subunit, this gateway is blocked and the following pathophysiological cascade occurs.
Muscle energy deficiency: Contracting skeletal muscle during exercise receives its ATP rapidly mainly through glycolysis. In GSD VII, loss of PFK function blocks progression of glycolysis downstream from F6P, so ATP rapidly runs short during high-intensity aerobic and anaerobic exercise. As a result, inability of muscle contraction (cramping), myalgia, decreased muscle strength during or immediately after exercise, and muscle stiffness occur. When muscle energy depletion becomes severe, cell membrane integrity is damaged and creatine kinase (CK) and myoglobin in the muscle cytoplasm leak into the blood, causing rhabdomyolysis.
Excessive accumulation of glycogen and glucose (glucose paradox): When F6P accumulates owing to PFK blockade, reverse conversion of phosphorylated glucose (G6P, F6P) is also inhibited and intracellular glucose-6-phosphate increases. The increased G6P stimulates glycogen synthesis and glycogen accumulates excessively in muscle. The distinctive "glucose paradox" is explained by this mechanism: with glucose infusion, F6P increases further and strengthens the PFK barrier, and as a result the glycolytic blockade worsens. This is observed clinically as a phenomenon in which glucose infusion before exercise worsens symptoms.
Hemolytic anemia: In red blood cells, PFK exists as an M-L hybrid tetrameric isozyme (M2L2, etc.), and with PFKM variants all isozymes containing the M subunit lose function, so red cell PFK activity falls to about 50% of the total. Because red blood cells have no mitochondria and glycolysis is their only source of energy, partial PFK deficiency leads to decreased ATP production, reduced defense against oxidative damage and red cell membrane instability. This causes chronic compensated hemolytic anemia, compensated by increased reticulocytes in the bone marrow. When hemolysis becomes severe, jaundice (hyperbilirubinemia) and cholelithiasis (pigment stones) may appear.
Polyglucosan accumulation: In muscle biopsies of some GSD VII patients, polyglucosan bodies, structurally abnormal glycogen distinguishable from normal glycogen, are found. This is interpreted as the result of excess glucose-1-phosphate due to PFK blockade disturbing glycogen branching. Polyglucosan accumulation is also found in nerve axons and may be the cause of neurological symptoms in some patients.
Tarui disease (GSD VII) has a very wide spectrum of clinical phenotypes. It is broadly classified into four phenotypes.
The classic form is the most common phenotype and is characterized by the following three main symptoms. First, exercise-induced muscle symptoms: after moderate- to high-intensity exercise (climbing stairs, running, lifting heavy objects), sudden myalgia, muscle cramps and decreased muscle strength occur. Rest of several minutes to tens of minutes after stopping exercise is needed for recovery. Second, myoglobinuria: reddish-brown urine appears after strenuous exercise, which is myoglobin leaked from muscle owing to rhabdomyolysis being excreted in the urine. Severe myoglobinuria can cause acute kidney failure and requires immediate fluid therapy. Third, compensated hemolytic anemia: chronic compensated hemolysis due to partial red cell PFK deficiency produces mild to moderate elevation of unconjugated bilirubin, increased reticulocytes and mild anemia. Jaundice may accompany it, and in the long term cholelithiasis (pigment gallstones) may occur. Nausea, vomiting and generalized fatigue after exercise are also common.
The severe infantile form is a rare but the most severe phenotype. Within several months of birth, severe hypotonia, progressive myopathy, cardiomyopathy and respiratory failure appear, often leading to early death. In this phenotype, PFK using the M subunit is presumed to lose function in cardiac muscle as well.
The late-onset form presents in middle age (30s–60s) with progressive fixed proximal muscle weakness. Persistent proximal muscle weakness (thigh and shoulder muscles) rather than exercise-induced myalgia is the main symptom, accompanied by CK elevation at a level suggesting myopathy. Differentiation from rheumatic myopathy and polymyositis is needed.
Isolated hemolytic anemia form is a phenotype with hemolytic anemia alone without muscle symptoms, occurring when certain PFKM variants affect only the liver or red blood cells.
Physical signs and laboratory findings of Tarui disease vary with phenotype and disease activity. In patients with the classic form, the physical examination at rest is generally normal, but characteristic findings are observed on exercise provocation testing and laboratory tests.
Exercise-induced signs: myalgia, muscle stiffness, and muscle weakness occur immediately after moderate-intensity exercise and resolve within minutes of stopping exercise. Within several hours after exercise, serum creatine kinase (CK) rises markedly (tens of times the resting baseline or more), and with myoglobinuria the urine turns reddish-brown to brown.
Blood test findings: increased reticulocytes (generally 5~15%), elevated indirect bilirubin, and increased serum LDH suggest chronic hemolysis. Serum uric acid may be elevated due to oxidation of hypoxanthine, a breakdown product of muscle ATP. Resting CK also often remains mildly to moderately elevated.
Non-ischemic forearm exercise test (NIFET): after forearm exercise without a blood pressure cuff, lactate and ammonia are measured. In normal individuals both lactate and ammonia rise, but in GSD VII a characteristic finding is seen: ammonia rises normally while lactate does not rise or even decreases. This is because lactate is not produced owing to the glycolytic block. This test is also useful for differentiation from McArdle disease (GSD V).
Glucose paradox: a clinical diagnostic clue is the phenomenon in which intravenous glucose before exercise paradoxically worsens exercise performance. This is because glucose loading increases fructose-6-phosphate, which deepens the PFK block.
Muscle biopsy findings: excessive glycogen accumulation and polyglucosan bodies on PAS staining. Loss of PFK activity on enzyme histochemistry. Increased cytoplasmic β-glycogen particles and polyglucosan granules on electron microscopy.
Newborn screening of the general population for Tarui disease (GSD VII) is not currently performed. This is because the disease is extremely rare and asymptomatic in the neonatal period, so a cost-effective screening method has not yet been established. Therefore, active symptom-based suspicion is the starting point of diagnosis.
Clinical-based screening: GSD VII should be suspected and further testing performed in the following clinical situations. (1) Children to adults with recurrent exercise-induced myalgia, muscle cramps, and exercise intolerance. (2) Episodes of post-exercise myoglobinuria (reddish-brown urine). (3) Mild hemolytic anemia of unknown cause with increased reticulocytes. (4) Marked elevation of CK after exercise. (5) Patients with exercise intolerance of Ashkenazi Jewish or Japanese ethnic background. (6) A history of paradoxically worsened exercise capacity after intravenous glucose (glucose paradox).
The non-ischemic forearm exercise test (NIFET) is the most important first-line screening tool. Method: after 1 minute of maximal forearm exercise (such as a hand grip) without a blood pressure cuff, blood lactate and ammonia are measured at 1, 2, 4, and 10 minutes. In GSD VII and GSD V (McArdle disease), ammonia rises but lactate does not. Unlike McArdle disease (PYGM deficiency), GSD VII also reduces red blood cell PFK activity by 50%, so measuring red blood cell PFK activity is used as an additional screening tool. If serum CK is persistently elevated (> 1,000 IU/L at rest), genetic testing with a myopathy panel (including GSD-related genes) is performed.
For definitive diagnosis of Tarui disease (GSD VII), molecular genetic testing of the PFKM gene is the current standard. When clinical symptoms and biochemical and functional tests make GSD VII likely, a gene panel or WES is performed first.
Step 1 — Clinical and functional testing: confirm non-rising lactate and normally rising ammonia on NIFET. Measure resting serum CK, reticulocyte count, bilirubin, and LDH to assess for hemolysis. Measure red blood cell PFK activity to confirm it is reduced to about 50% (about 50% of normal red blood cell PFK = a surrogate marker of PFKM deficiency).
Step 2 — Molecular genetic testing: confirm pathogenic PFKM variants with a next-generation sequencing (NGS)-based myopathy/GSD gene panel or whole exome sequencing (WES). The diagnosis is confirmed when a pathogenic variant is found in each of both alleles. In Ashkenazi Jewish or Japanese patients, performing targeted testing first for the ethnic-specific founder variants (exon 5 deletion, p.Arg41Ter) improves diagnostic efficiency.
Step 3 — Muscle biopsy (optional): performed when molecular genetic testing results are unclear. Diagnostic criteria are loss of PFK enzyme histochemical staining on muscle biopsy, excessive accumulation of glycogen and polyglucosan on PAS staining, and biochemical PFK enzyme activity measurement (less than 5% of normal or complete loss).
Differential diagnosis: McArdle disease (GSD V, PYGM): NIFET findings are similar, but red blood cell PFK is normal. The 'second wind' phenomenon after exercise is characteristic of GSD V, whereas the glucose paradox is characteristic of GSD VII. Other myopathies (mitochondrial myopathy, fatty acid oxidation disorders, polymyositis): elevated serum CK and exercise intolerance are similar, but they are distinguished by NIFET results, enzyme assays, and genetic testing. Autoimmune hemolytic anemia: a negative antiglobulin test (Coombs test) is characteristic of hemolysis in Tarui disease.
Curative treatment for Tarui disease (GSD VII) (enzyme replacement therapy, gene therapy) is still at the clinical stage, and there is no approved specific therapy. Current treatment aims at symptom management and prevention of complications.
Exercise management is the most important treatment principle. Avoid high-intensity anaerobic exercise and high-intensity resistance exercise, which can cause rhabdomyolysis and myoglobinuria. Low-intensity aerobic exercise (walking, swimming, cycling) can often be performed without symptoms through energy supply from fatty acid oxidation. Adequate warm-up before exercise (gradual increase from low intensity) and sufficient fluid intake are recommended. A safe exercise plan is established by determining each patient's individual exercise tolerance range.
Dietary therapy: a glucose-rich meal can worsen muscle symptoms because of the glucose paradox, so simple sugar intake before exercise is avoided. Some case reports and small studies indicate that a high-protein, high-fat, low-carbohydrate (ketogenic) diet may improve exercise capacity by using fatty acids and ketone bodies as energy substrates. There are also reports that fat intake before exercise (medium-chain triglycerides, MCT) may help. Randomized controlled studies on the long-term effects and safety of the ketogenic diet are still lacking.
Management of acute rhabdomyolysis: when myoglobinuria occurs after strenuous exercise, immediate fluid therapy (intravenous normal saline, maintaining urine output > 200 mL/h) is used to prevent acute renal tubular injury and acute renal failure. Alkalinizing the urine (sodium bicarbonate administration) is used to minimize myoglobin deposition.
Management of hemolytic anemia: to replace folate consumed by chronic hemolysis, folic acid 1 mg/day is supplemented. If cholelithiasis develops, cholecystectomy is considered depending on symptoms. Transfusion may be needed for severe anemia (Hb < 8 g/dL).
Future treatment research: research is ongoing on the muscle energy-supplementing effect of the ketogenic diet, and gene therapy (AAV-based) and mRNA therapy to restore PFKM gene function are also at the preclinical stage. Although no GSD VII-specific clinical trial has started, the development of gene therapy platforms for GSD in general is accelerating.
The prognosis of patients with classic Tarui disease is relatively stable when exercise restriction and lifestyle management are followed. Exercise-induced myalgia and cramps can be largely prevented by avoiding high-intensity exercise, and chronic hemolytic anemia is often mild and managed with folate supplementation. Intellectual function and cardiopulmonary function (except in the severe infantile form) remain normal.
Major complications and factors worsening the prognosis are as follows. Acute renal failure is the most serious acute complication occurring after an episode of severe myoglobinuria; most cases recover with immediate fluid therapy, but recurrence can progress to chronic kidney damage. The severe infantile form carries a high risk of death in infancy from cardiomyopathy and respiratory failure. The late-onset form involves progressive fixed proximal muscle weakness that can reduce activities of daily living, but it tends to progress more slowly than McArdle disease (GSD V). Cholelithiasis is a risk factor for cholecystitis and bile duct obstruction due to pigment gallstone formation. In the long term, neurological complications (peripheral neuropathy associated with polyglucosan accumulation) are rarely reported.
Through genetic counseling, molecular genetic testing and prenatal diagnosis (chorionic villus sampling, amniocentesis, PGT-M) are applied in at-risk families. As secondary prevention after diagnosis, patients are educated to avoid high-intensity exercise and to warm up appropriately before exercise, and an exercise prescription is provided with exercise intensity adjusted to individual tolerance. During fever or infectious illness, activity is minimized and sufficient fluids are taken. Patients are educated on the importance of immediate emergency room visit and fluid therapy for exercise-induced myoglobinuria. Large intake of glucose (sugar) before exercise is avoided, and a pre-exercise meal centered on fat and protein is recommended. Disease activity is monitored through regular follow-up of renal function, hemoglobin, reticulocyte count, and CK.
Tarui S, Okuno G, Ikura Y, et al. Phosphofructokinase deficiency in skeletal muscle: a new type of glycogenosis. Biochem Biophys Res Commun. 1965;19(4):517-523. DOI: 10.1016/0006-291X(65)90156-7. PMID: 4378918.
Nakajima H, Raben N, Hamaguchi T, Yamasaki T. Phosphofructokinase deficiency; past, present and future. Curr Mol Med. 2002;2(2):197-212. DOI: 10.2174/1566524024605734. PMID: 11949934.
Musumeci O, Bruno C, Mongini T, et al. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord. 2012;22(4):325-330. DOI: 10.1016/j.nmd.2011.10.022. PMID: 22137466.
Vorgerd M, Zange J, Kley R, et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in patients with myophosphorylase deficiency. Arch Neurol. 2002;59(1):97-101. DOI: 10.1001/archneur.59.1.97. PMID: 11790237.
Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2013;6:CD004760. DOI: 10.1002/14651858.CD004760.pub4. PMID: 23740603.
Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology. 2004;62(1):82-86. DOI: 10.1212/01.wnl.0000104670.18494.82. PMID: 14718702.
Comi GP, Fortunato F, Lucchiari S, et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol. 2001;50(2):202-207. DOI: 10.1002/ana.1095. PMID: 11506403.
Fernandez-Cadenas I, Andreu AL, Gamez J, et al. Splicing and pathology in muscle phosphofructokinase deficiency (GSD VII). Neurology. 2003;61(11):1557-1563. DOI: 10.1212/01.wnl.0000096019.70012.8d. PMID: 14663039.
Scalco RS, Gardiner AR, Pitceathly RD, et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. 2015;10:51. DOI: 10.1186/s13023-015-0264-3. PMID: 25929686.
Pietersen CY, Lammens M, Smet J, et al. Novel PFKM mutation in glycogen storage disease type VII: a case report with comprehensive exploration. Front Genet. 2024;15:1386921. DOI: 10.3389/fgene.2024.1386921. PMID: 39224744.